Published August 12, 2024
| Version v1
Journal article
Pustular mycosis fungoides has a poor outcome: a multicentric clinico-pathological and molecular case series study
Creators
- Bontoux, Christophe
- Badrignans, Marine
- Afach, Sivem
- Sbidian, Emilie
- Mboumba, Diana-Laure
- Ingen-Housz-Oro, Saskia
- Claudel, Alexis
- Aubriot-Lorton, Marie-Hélène
- Chong-Si-Tsaon, Arnaud
- Le Masson, Gilles
- Attencourt, Christophe
- Dubois, Romain
- Beltzung, Fanny
- Koubaa, Wafa
- Beltraminelli, Helmut
- Cardot-Leccia, Nathalie
- Balme, Brigitte
- Nguyen, Anh Tuan
- Bagny, Kelly
- Legoupil, Delphine
- Moustaghfir, Ibtissam
- Denamps, Juliette
- Mortier, Laurent
- Hammami-Ghorbel, Houda
- Skrek, Sergey
- Rafaa, Mostefa
- Fougerousse, Anne-Claire
- Deschamps, Thibaut
- Dalle, Stéphane
- D'incan, Michel
- Chaby, Guillaume
- Beylot-Barry, Marie
- Dalac, Sophie
- Ortonne, Nicolas
Contributors
Others:
- Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) ; Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Centre de Recherches en Cancérologie de Toulouse (CRCT) ; Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Laboratoire de Pathologie Clinique et Expérimentale. Hôpital Pasteur [Nice] ; Hôpital Pasteur [Nice] (CHU)
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UniCA)
- Département de pathologie [Mondor] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE) ; Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Service de dermatologie [Mondor] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Institut Mondor de Recherche Biomédicale (IMRB) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- CHU Henri Mondor [Créteil]
- Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- IMRB - NFL/"Neurofibromatosis and Lymphoma Oncogenesis" [Créteil] (U955 Inserm - UPEC) ; Institut Mondor de Recherche Biomédicale (IMRB) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Service de Pathologie [CHU de Dijon] ; Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)
- Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion]
- CHRU Brest, Pôle de Biologie Pathologie (CHU - BREST - Biologie pathologie) ; Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
- Anatomie et Cytologie Pathologiques [CHU Amiens] ; CHU Amiens-Picardie
- CHirurgie, IMagerie et REgénération tissulaire de l'extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 (CHIMERE) ; Université de Picardie Jules Verne (UPJV)
- Hôpital Claude Huriez [Lille] ; Centre Hospitalier Régional Universitaire [CHU Lille] (CHRU Lille)
- Hôpital Haut-Lévêque - CHU de Bordeaux (Centre médico chirurgical Magellan)
- Hôpital Habib Thameur [Tunis]
- Inselspital Bern
- Hôpital Pasteur [Nice] (CHU)
- Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS) ; Hospices Civils de Lyon (HCL)
- Hôpital d'Instruction des Armées Begin [Saint-Mandé, France] (HIA Begin) ; Service de Santé des Armées
- Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
- Service de Dermatologie [CHU Nantes] ; Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)
- Service de dermatologie [CHU d'Amiens-Picardie] ; CHU Amiens-Picardie
- North Western State Medical University Named After I.I Mechnikoff ; Partenaires INRAE
- Centre Hospitalier Sud Francilien
- Centre hospitalier de Valence
- Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL) ; Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Service Dermatologie et Oncologie Cutanée [CHU Clermont-Ferrand] ; CHU Estaing [Clermont-Ferrand] ; CHU Clermont-Ferrand-CHU Clermont-Ferrand-Pôle Spécialités médicales et chirurgicales [CHU Clermont-Ferrand] ; CHU Clermont-Ferrand
- Service de dermatologie Hôpital Saint-André Bordeaux ; Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)
- Service de Dermatologie (CHU de Dijon) ; Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)
Description
Background Mycosis fungoides (MF) has usually an indolent course. However, some patients develop a more aggressive disease and few prognostic parameters have been identified. Isolated cases of pustular MF (pMF) suggest an unfavourable prognosis. Objectives We aim to describe the clinico-pathological characteristics and prognostic value of pMF. Methods We retrospectively collected data of all cases of MF with histological pustules diagnosed from 2009 to 2020. The outcomes and clinico-pathological characteristics of pMF at diagnosis (pMFD) were compared to those of a cohort of non-pustular MF (NpMF). Results 33 pMF (including 22 pMFD) and 86 NpMF cases were included. The median age at diagnosis of pMF was 61 years [IQR=50-75]. The median follow-up of pMFD was 32 months [IQR=14-49]. Clinically, 33% of pMF had pustules. Large-cell transformation (LCT) occurred in 17 cases. pMFD were at a significantly more advanced-stage and more showed LCT at diagnosis than NpMF (50% vs 7%, p<0.001 and 23% vs 0%, p<0.001, respectively). In multivariate Cox analysis, the presence of histological pustule at diagnostic was associated with shorter OS in all patients (HR=13.90, CI95%[2.43-79]; p=0.003), and in early-stage patients (HR=11.09, CI95%[1.56-78.82]; p=0.02). In multivariate Fine and Gray model analysis, pMFD was associated with a higher cumulative incidence of LCT (SHR=13.90, CI95% [2.43-79]; p=0.003) in all patients. Median OS after the occurrence of histological pustules during follow-up of all pMF patients was 37 months, with a five-year OS of 25% (CI95% [0.06-0.5]). Conclusion pMF often follows an aggressive course, with a high risk of LCT and shorter survival, even for early-stage patients. Histological pustules at diagnostic of MF might represent an independent poor prognostic factor, to be confirmed by further studies. Because pustules are not always clinically identified, histological pustules should be mentioned in pathology reports of MF and prompt discussion of a closer follow-up.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.science/hal-04675180
- URN
- urn:oai:HAL:hal-04675180v1
Origin repository
- Origin repository
- UNICA